LTS signs research collaboration agreement for Micro Array Patches
LTS Lohmann Therapie-Systeme AG has entered into a research collaboration agreement for the evaluation of LTS Micro Array Patch (MAP) technology.
LTS presents Microarray Patches at the Developments and Innovations in the Drug Delivery Market
Dr. Sebastian Braun will present “Dissolvable microarray systems - An industry view regarding development and manufacturing of a new dosage form”.
Micro Array Patches – The future of pain-free injections, self-applied by the patient
What are the options to make your injectable product patient [...]
LTS receives the “Highest Reputation” award
The "Highest Reputation" award for LTS. The study assessed the reputation for Management, Sustainability, Products and Services, Performance as Employer, and Business Performance.
LTS marketing campaign, a complete success – awarded!
LTS's very emotional "Animals" marketing campaign has received an extraordinary positive response. The LTS campaign was awarded 2 times.
LTS and LIVZON enter into license and collaboration agreement to develop and commercialize ASENAPINE TTS
LTS AG and Livzon Pharmaceutical Group Inc. announced today that the companies have entered into an exclusive license and collaboration agreement. LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).
LTS Oral Thin Film Technology – Adaptable Like a Chameleon
Understand the components and science of OTFs and how they [...]
LTS appoints Bas van Buijtenen as new Chief Executive Officer
LTS Lohmann Therapie-Systeme AG is very pleased to announce the appointment of Mr. Bas van Buijtenen to the role of Chief Executive Officer effective 1 June 2020.
Completion of solar panel installation at LTS Corp.
LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is pleased to announce the completion of the installation of solar panels atop of its warehouse building of its US affiliate, LTS Lohmann Therapy Systems, Corp.
LTS announces the appointment of David Doles as new President and Chief Executive Officer for its US affiliate LTS Corp.
LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is very pleased to announce the appointment of Mr. David Doles as the President and Chief Executive Officer for its US affiliate, LTS Lohmann Therapy Systems, Corp. effective 1 January 2020.